All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Prof. Charles Craddock | EBMT 2018 | Can hypomethylating agents prevent post-transplant relapse in AML?
Bookmark this article
Prof. Charles Craddock (chair of our European Steering Committee) from Queen Elizabeth Hospital, Birmingham, UK, discusses strategies to reduce post-transplant relapse in AML at the 44th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, 18–21 Mar 2018, Lisbon, PT. He noted that delaying the GvL effect using agents such as gilteritinib, sorafenib and azacitidine may be a strategy for reducing post-transplant relapse.
Can hypomethylating agents prevent post-transplant relapse in AML?
More about...
Your opinion matters
5 votes - 1 hours left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox